Terns Pharmaceuticals, INC. (TERN) — SEC Filings

Overview

Terns Pharmaceuticals, INC. (TERN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a SC14D9C filed on Mar 25, 2026: This SC14D9C filing from Terns Pharmaceuticals, Inc. on March 25, 2026, indicates a written communication related to a third-party tender offer. While the filing itself doesn't detail the offer, it signals that Terns Pharmaceuticals is the subject of a potential acquisition or significant share purc

Sentiment Summary

Across 49 filings, the sentiment breakdown is: 1 bearish, 45 neutral, 3 mixed. The dominant filing sentiment for Terns Pharmaceuticals, INC. is neutral.

Filing Type Overview

Terns Pharmaceuticals, INC. (TERN) has filed 1 SC14D9C, 18 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 11 SC 13G/A, 7 SC 13G, 2 SC 13D/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (49)

• Terns Pharma Files SC14D9C for Third-Party Tender Offer — SC14D9C · Mar 25, 2026
  This SC14D9C filing from Terns Pharmaceuticals, Inc. on March 25, 2026, indicates a written communication related to a third-party tender offer. While the filin
• Terns Pharma Enters Material Definitive Agreement — 8-K · Mar 25, 2026
  Terns Pharmaceuticals, Inc. filed an 8-K on March 25, 2026, reporting an "Entry into a Material Definitive Agreement" as of March 24, 2026. This indicates the c
• Terns Pharmaceuticals Files 8-K — 8-K · Dec 11, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on December 11, 2025, reporting an event that occurred on December 9, 2025. The filing is categorized under 'Other Even
• Terns Pharmaceuticals Files 8-K — 8-K · Dec 8, 2025 Risk: low
  On December 8, 2025, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD Di
• Terns Pharma Widens Q3 Loss Amid Rising R&D Spend — 10-Q · Nov 10, 2025 Risk: high
  Terns Pharmaceuticals, Inc. reported a net loss of $24.635 million for the three months ended September 30, 2025, an increase from a net loss of $21.945 million
• Terns Pharmaceuticals Files 8-K — 8-K · Nov 3, 2025 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on November 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures,
• Terns Pharmaceuticals Files 8-K — 8-K · Oct 22, 2025 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting on events that occurred on October 21, 2025. The filing pertains to 'Other Events' and '
• Terns Narrows Q2 Loss Amid R&D Cuts, Cash Runway to H2 2026 — 10-Q · Aug 5, 2025 Risk: high
  Terns Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net l
• Terns Pharmaceuticals Reports Shareholder Vote Matter — 8-K · Jun 16, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting on a matter submitted to a vote of its security holders on June 11, 2025. The filing does n
• Terns Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and fair
• Terns Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Terns Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting scheduled for June 11, 2025. The filing out
• Terns Pharmaceuticals Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The filing details its business operat
• Terns Pharmaceuticals Appoints New Director — 8-K · Feb 24, 2025 Risk: low
  Terns Pharmaceuticals, Inc. announced on February 22, 2025, a change in its board of directors. Specifically, Dr. Andrew A. Adams has been appointed as a Class
• Terns Pharmaceuticals Files 8-K on Executive Changes — 8-K · Feb 20, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on February 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment o
• Terns Pharmaceuticals Announces Executive Changes and New Director — 8-K · Feb 6, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. announced on February 1, 2025, the departure of its Chief Medical Officer, Dr. Sarah Johnson, effective immediately. The company als
• Terns Pharmaceuticals Files 8-K — 8-K · Dec 3, 2024 Risk: low
  On December 3, 2024, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no
• Terns Pharmaceuticals Relocates Principal Executive Offices — 8-K · Nov 18, 2024 Risk: low
  Terns Pharmaceuticals, Inc. announced on November 14, 2024, a change in its principal executive offices to 1065 East Hillsdale Blvd., Suite 100, Foster City, Ca
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Terns Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Terns Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 12, 2024, detailing its financial performance for the period ending September 30, 2024. Th
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 5, 2024
• SC 13G Filing — SC 13G · Oct 24, 2024
• OrbiMed Adjusts Terns Pharma Stake to 5.1% — SC 13D/A · Sep 16, 2024 Risk: medium
  On September 16, 2024, OrbiMed Advisors LLC and its affiliates filed an amendment (No. 5) to their Schedule 13D for Terns Pharmaceuticals, Inc. This filing indi
• Terns Pharmaceuticals Files 8-K — 8-K · Sep 12, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on September 12, 2024, reporting an event on September 10, 2024. The filing primarily concerns financial statements and
• Terns Pharmaceuticals Files 8-K — 8-K · Sep 9, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on September 9, 2024, reporting on other events and financial statements. The filing does not contain specific details
• Terns Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  Terns Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Terns Pharmaceuticals Appoints New Director — 8-K · Jul 29, 2024 Risk: low
  Terns Pharmaceuticals, Inc. announced on July 23, 2024, a change in its board of directors. Specifically, Dr. David J. Earp has been appointed as a new Class II
• SC 13G Filing — SC 13G · Jul 22, 2024
• OrbiMed Adjusts Terns Pharma Stake to 5.1% — SC 13D/A · Jul 18, 2024 Risk: medium
  On July 18, 2024, OrbiMed Advisors LLC and its affiliates filed an amendment (Amendment No. 4) to their Schedule 13D for Terns Pharmaceuticals, Inc. The filing
• Terns Pharmaceuticals Enters Loan Agreement — 8-K · Jul 3, 2024 Risk: medium
  On July 1, 2024, Terns Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. Th
• Terns Pharmaceuticals Files 8-K on Shareholder Vote — 8-K · Jun 12, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders on June 10, 2024. The filing details the
• SC 13G Filing — SC 13G · Jun 7, 2024
• SC 13G/A Filing — SC 13G/A · Jun 7, 2024
• Terns Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Terns Pharmaceuticals, Inc. (TERN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Terns Pharmaceuticals, Inc. filed a 10-Q report for the period
• Terns Pharmaceuticals Files 8-K — 8-K · Apr 29, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on April 29, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Terns Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 25, 2024 Risk:
  Terns Pharmaceuticals, Inc. (TERN) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Stockholders for Terns Pharmaceu
• Terns Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024 Risk: medium
  Terns Pharmaceuticals, Inc. (TERN) filed a Annual Report (10-K) with the SEC on March 14, 2024. Terns Pharmaceuticals, Inc. filed its annual report on Form 10-K
• SC 13G Filing — SC 13G · Mar 7, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• FMR LLC & Abigail Johnson Trim Terns Pharma Stake to 4.839% — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their holdings in Terns Pharmaceuticals, Inc. (TERNS). As of Februar
• Terns Pharma 8-K: Leadership Changes & Comp Arrangements — 8-K · Feb 7, 2024
  Terns Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 6, 2024. This filing, under Item 5.02, pertains to ch
• BlackRock Discloses Passive Stake in Terns Pharma — SC 13G · Jan 31, 2024
  BlackRock, Inc., a major investment firm, filed an SC 13G on January 31, 2024, disclosing its ownership of Terns Pharmaceuticals, Inc. (Terns Pharma) common sto
• Millennium Affiliate Discloses Stake in Terns Pharmaceuticals — SC 13G · Jan 25, 2024
  Integrated Core Strategies (US) LLC, part of Millennium Management LLC, filed an SC 13G on January 25, 2024, disclosing its ownership of Terns Pharmaceuticals,

Frequently Asked Questions